This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pivotal Findings On Autoimmune Disease Shared At Lupus Research Institute "Forum For Discovery"

NEW YORK, Oct. 25, 2012 /PRNewswire/ -- The 12 th annual Lupus Research Institute (LRI) Scientific Conference "Forum for Discovery" brought together more than 60 of the country's top experts in the field to focus their talent on addressing the critical questions in the autoimmune disease lupus. LRI-funded investigators presented new findings on a broad range of topics including genetic factors that predispose certain individuals to lupus, how the lupus immune system turns against the body, and novel approaches to treat the disease.

A focal question of this year's two-day think tank was how to stem the destructive cycle of inflammation and organ damage in lupus. In lupus, inflammation is one of the most common causes of damage to vital organs such as the heart, brain, and kidneys. It results from the immune system attacking the body's own tissues as if there were an infection to fight off.  Two guest speakers, Drs. Eric Pamer at Memorial Sloan-Kettering Cancer Center and Charles Serhan at Harvard Medical School, shared pivotal advances in inflammation, stimulating an exchange on how their discoveries can influence lupus research.

LRI-funded investigators reported breakthrough results that have implications not only in lupus but also for the autoimmune diseases affecting 23.5 million Americans.  Findings include:
  • New insight into how the brain talks to the immune system to suppress inflammation in lupus was shared by Dr. Jane Salmon at Hospital for Special Surgery. Dr. Salmon's discovery may lead to a whole new approach to lupus treatment.
  • Dr. Carla Rothlin at Yale University reported that a blood protein (protein S) known to be low in lupus patients helps to turn off inflammation. This discovery could lead to new drugs that harness the power of protein S to treat lupus and other autoimmune diseases.
  • Dr. Anne Davidson, The Feinstein Institute, is using a new approach to find out why an existing rheumatoid arthritis drug anti-TNF can be protective in lupus kidney disease but also induces potentially harmful autoantibodies. Her findings suggest it may be possible to develop improved anti-TNF drugs that eliminate negative effects.
  • The "hot" new topic in lupus, epigenetics, was the focus of a presentation by Dr. Amr Sawalha at University of Michigan. Epigenetics tells us how the environment may activate a gene that triggers lupus; importantly this change can also be passed on to the next generation. Dr. Sawalha's work brings a long-sought missing piece to the puzzle of how lupus is inherited.

"The work presented at this Forum demonstrates the tremendous success of the LRI's strategic approach of funding the most novel scientific ideas in lupus," noted world-leading immunologist Dr. William Paul, LRI Scientific Advisory Board Chairman and National Academy of Sciences member. "The LRI continues to thrive on the union of scientists with the passion to pursue the most innovative scientific ideas with the patients and families who share that same passion to find new treatments and a cure for the disease."

Advancing new lupus treatments

Overcoming the many serious challenges impeding lupus drug development was the focus of an industry forum bringing together government, academia, and industry. One particularly well-received suggestion was to reduce the higher failure rate of drugs at late stage clinical trials by using biological tests (biomarkers) to show much earlier in development whether a drug is safe and has the expected biological effect.   

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,757.91 +138.40 0.79%
S&P 500 2,077.42 +14.31 0.69%
NASDAQ 5,013.1230 +26.2560 0.53%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs